A study of 662 individuals found that CSF GAP-43 concentration was increased significantly in clinical AD and CBS patients, while there were no concentration differences between both the control and clinical PSP groups, and behavioral variant FTD (bvFTD), and amyotrophic lateral sclerosis (ALS) with FTD groups5. This evidence concerns the gene GAP43 and Alzheimer disease.